FibroGen Inc represents a commitment to innovative biopharmaceutical research and development. The company focuses on discovering, developing, and commercializing transformative therapies for unmet medical needs. FibroGen believes in a patient-centric approach, striving to improve the lives of individuals through groundbreaking medical advancements. With a strong emphasis on scientific excellence and a dedicated team, FibroGen pursues cutting-edge treatments and therapies to address diseases such as anemia, fibrosis, and cancer. The company's corporate philosophy is built on integrity, collaboration, and a drive for meaningful impact in the field of biotechnology. FibroGen Inc aims to bring hope and improved health outcomes to patients worldwide.

FibroGen Inc is primarily present in the United States and China. With headquarters in San Francisco, California, the company operates in various states across the US, including California, Massachusetts, and Washington. In addition, FibroGen Inc has a significant presence in China, where it has established partnerships and collaborations for research, development, and commercialization of its products. This dual presence in the two prominent economies allows FibroGen Inc to target and cater to a larger market, maximizing its growth opportunities and expanding its global footprint.

FibroGen Inc, a renowned biopharmaceutical company, has achieved several significant milestones. Firstly, the company received FDA approval for roxadustat, their breakthrough anemia treatment. Additionally, FibroGen Inc successfully completed Phase 3 clinical trials for roxadustat, establishing its efficacy and safety. The company also entered into strategic collaborations with global pharmaceutical giants, such as AstraZeneca and Astellas Pharma, to expand the reach of their innovative therapies. FibroGen Inc's dedication to research and development has led to the discovery of novel treatments for serious medical conditions, positively impacting patients worldwide. Their relentless pursuit of scientific advancements has earned them a prominent position in the biopharmaceutical industry.

FibroGen Inc. is a biopharmaceutical company known for its cutting-edge research and development in treating serious unmet medical needs. Established in 1993 and headquartered in San Francisco, California, FibroGen has been at the forefront of developing novel therapies to address conditions such as anemia, fibrosis, and cancer. The company's expertise lies in utilizing its advanced platform technologies, including tissue repair and fibrosis, to develop innovative treatments. FibroGen has successfully brought several drugs to market, including roxadustat, which treats anemia in patients with chronic kidney disease. Combining a deep commitment to scientific advancement and patient well-being, FibroGen strives to revolutionize healthcare with its groundbreaking pharmaceutical solutions.

The main competitors of FibroGen Inc in the market include companies like Gilead Sciences, Inc., Akebia Therapeutics, Inc., and GlaxoSmithKline plc.

FibroGen Inc is primarily active in the biotechnology and pharmaceutical industries.

FibroGen Inc has a business model focused on the development and commercialization of innovative therapies for serious unmet medical needs. The company specializes in the research and development of biologics, particularly in the areas of anemia, fibrosis, and cancer. FibroGen Inc collaborates with partners to advance their pipeline of potential medicines, aiming to improve the lives of patients worldwide. Through its scientific expertise and strategic collaborations, FibroGen Inc aims to bring new treatment options to market that address various disease indications and improve patient outcomes.

KGV za FibroGen trenutno ne može biti izračunato.

KUV za FibroGen trenutno ne može biti izračunat.

AlleAktien kvalitativni skor za FibroGen je 5/10.

Prihod trenutno ne može biti izračunat za FibroGen.

Profit trenutno ne može biti izračunat za FibroGen.

FibroGen Inc. is a biopharmaceutical company specializing in the development of innovative therapies for diseases such as anemia, cancer, and fibrosis. The company is headquartered in San Francisco and has branches in China and Denmark. The company's business model is based on researching and developing therapeutic molecules that stimulate the body's production of natural hormones and erythropoietin (EPO). FibroGen has developed a proprietary technology platform for developing novel drugs based on specific biological mechanisms. Their research and development focus includes anemia treatment, cancer treatment, and fibrosis treatment. They have developed products such as Roxadustat for anemia in chronic kidney disease, Pamrevlumab for cancer treatment, and Pamrevlumab for idiopathic pulmonary fibrosis and systemic sclerosis. They also have partnerships with other pharmaceutical companies like Astellas and AstraZeneca to bring their products to market.

FibroGen isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za FibroGen trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od FibroGen je US31572Q8087.

WKN od FibroGen je A12EZ0.

Oznaka za praćenje akcija kompanije FibroGen je FGEN.

U poslednjih 12 meseci, FibroGen je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, FibroGen će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od FibroGen trenutno iznosi .

FibroGen isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

FibroGen je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

FibroGen se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od FibroGen od 3. 8. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 3. 8. 2024..

Isplata poslednje dividende izvršena je 3. 8. 2024..

U godini 2023 kompanija FibroGen je isplatila 0 USD kao dividende.

Dividende od FibroGen se isplaćuju u USD.